Hoth Therapeutics Inc. (HOTH) shares gained 11.02% in after-hours on Tuesday, August 10, 2021, and closed the daily trading at $1.41 per share. In the regular trading session on Tuesday, HOTH’s stock lost 3.79%. HOTH shares have fallen 59.42% over the last 12 months, and they have moved down 12.41% in the past week. Over the past three months, the stock has lost 7.30%, while over the past six months, it has declined 47.30%.
Let’s have a look at its recent news.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now.
HOTH Initiated Preclinical Study of HT-ALZ
On August 2, 2021, Hoth Therapeutics, Inc initiated its preclinical study utilizing Hoth’s HT-ALZ in an animal model.
The study will determine the effects of HT-ALZ on behavioural and pathological markers of Alzheimer’s disease and determine if HT-ALZ can improve learning and memory in an animal model of Alzheimer’s disease.
HOTH reported BioLexa results
On June 28, 2021, Hoth Therapeutics, Inc announced the safety results in Cohort 1 of its first in a human clinical trial of the proprietary BioLexa platform to treat atopic dermatitis, also known as eczema.
BioLexa was administered twice per day for 14 days to the first ten subjects within Cohort 1. The interim safety review indicates that BioLexa was well tolerated with no serious adverse events and no drug-related treatment-emergent adverse events observed.
HOTH Research Agreement with Washington University
On June 7, 2021, Hoth Therapeutics, Inc entered into a Sponsored Research Agreement with Washington University in St. Louis to support the continued research and development of HT-ALZ, which is a novel therapeutic for the treatment of symptoms related to Alzheimer’s disease.
HT-KIT positive results
On June 3, 2021, Hoth Therapeutics, Inc announced to share positive results from a preclinical trial during its shareholder presentation, reinforcing the potential of HT-KIT, a new molecular entity under development for the treatment of mast cell-derived cancers and anaphylaxis.
HT-KIT is an mRNA frame-shifting therapeutic designed to specifically target the receptor tyrosine kinase KIT, which is required for the proliferation, survival and differentiation of bone marrow-derived hematopoietic stem cells.
Key findings of HT-KIT
- Reduces KIT expression and induces apoptosis of neoplastic human mast cells
- Inhibits tumour growth in humanized xenograft mast cell neoplasia models
- Reduces liver infiltration of neoplastic mast cells
Participation in the recent conference
Hoth Therapeutics, Inc recently participated as an exhibitor at the American Society of Clinical Oncology (ASCO) Annual Meeting, which was held from May 24th through July 6, 2021.
Well, as of this writing, we had no recent news which could justify its mixed performance on Tuesday. We hope that HOTH shares will continue to climb up in the coming days